Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.4/2124
Registo completo
Campo DCValorIdioma
dc.contributor.authorMarques, JP-
dc.contributor.authorFarinha, C-
dc.contributor.authorCosta, MÂ-
dc.contributor.authorFerrão, Â-
dc.contributor.authorNunes, S-
dc.contributor.authorSilva, R-
dc.date.accessioned2017-09-26T15:47:39Z-
dc.date.available2017-09-26T15:47:39Z-
dc.date.issued2017-08-28-
dc.identifier.citationBMJ Open. 2017 Aug 28;7(8):e015785.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.4/2124-
dc.description.abstractPURPOSE: The purpose of this study is to compare the efficacy and safety of intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT) versus IVA with verteporfin PDT (vPDT) in a Caucasian population with treatment-naive polypoidal choroidal vasculopathy (PCV), enrolling into a treat and extend (T&E) regimen. METHODS AND ANALYSIS: Randomised, double-masked, sham-controlled, multicentre phase 4 investigator-driven clinical trial. The primary outcomes are (1) change in best-corrected visual acuity (BCVA) from baseline and (2) polyp regression at week 52, assessed by indocyanine green angiography (ICGA). Fifty patients with treatment-naive PCV will be recruited from Portuguese and Spanish clinical sites. Eligible patients will receive monthly IVA for 3 months (week 0, week 4 and week 8). At week 16, all patients will repeat ICGA and undergo central randomisation (1:1 ratio) into one of the following groups: Group 1-IVA T&E + vPDT; Group 2-IVA T&E + sPDT. PDT will be performed at week 16, week 28 and week 40 in the presence of active polyps. After week 16, the presence of macular fluid on optical coherence tomography will determine the schedule of observations. When present, the interval between visits/injections will decrease 2 weeks (minimum 6 weeks). When not, the interval between visits/injections will increase 2 weeks (maximum 12 weeks). Efficacy will be evaluated based on BCVA, central retinal thickness and polyp regression. Safety parameters will include assessment of intraocular pressure, adverse events and serious adverse events. ETHICS AND DISSEMINATION: This study was designed and shall be implemented and reported in accordance with the International Conference on Harmonisation (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice, with applicable local regulations and with the ethical principles laid down in the Declaration of Helsinki. The study received approval from Comissão de Ética para a Investigação Clínica and Comité Ético de investigación Clínica del Hospital Universitari de Bellvitge. TRIAL REGISTRATION NUMBER: This study is registered under the EudraCT number: 2015-001368-20 and the ClinicalTrials.gov Identifier: NCT02495181.pt_PT
dc.language.isoengpt_PT
dc.rightsopenAccesspt_PT
dc.subjectFotoquimioterapiapt_PT
dc.subjectReceptores de Factores de Crescimento do Endotélio Vascularpt_PT
dc.subjectAcuidade Visualpt_PT
dc.subjectDoenças da Coróidept_PT
dc.subjectPólipospt_PT
dc.titleProtocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC studypt_PT
dc.typearticlept_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
degois.publication.firstPagee015785pt_PT
degois.publication.issue8pt_PT
dc.peerreviewedyespt_PT
degois.publication.volume7pt_PT
dc.identifier.doi10.1136/bmjopen-2016-015785pt_PT
Aparece nas colecções:OFT - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
e015785.full.pdf550,79 kBAdobe PDFVer/Abrir


Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.